Prevelence of Liver Disease-Related Outcomes in People With HIV

Launched by SHANGHAI PUBLIC HEALTH CLINICAL CENTER · Apr 15, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how liver diseases affect people living with HIV. Specifically, it focuses on conditions like metabolic associated fatty liver disease (MAFLD) and liver fibrosis, which can develop when the liver becomes damaged. While antiretroviral therapy helps control HIV and improves patients' lives, issues like liver disease are becoming more common in these patients. The goal of the study is to better understand how liver fibrosis develops in people with HIV, as it can lead to serious problems like liver failure or the need for a liver transplant.

To participate in this trial, individuals need to be between 18 and 70 years old and must be HIV positive. They should also have had specific tests (abdominal ultrasound and Fibroscan) done between December 2019 and April 2020 at the hospital. However, people with certain conditions, such as excessive alcohol consumption or other liver diseases, will not be eligible. Participants will be followed in the outpatient department for several years, and this research aims to improve the understanding of liver health in people living with HIV.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Aged between 18 and 70 years old
• • 2. HIV positive individuls
• • 3. Had abdominal ultrasound and Fibroscan done between December 2019 and April 2020, with available data of LSM and CAP, and had routine follow - up at our hospital's outpatient department from April 2020 to April 2025.
• Exclusion Criteria:
• • 1. Men with excessive alcohol consumption (more than 210g/week) and women with excessive alcohol consumption (more than 140g/week).
• • 2. Suffering from other liver diseases, such as viral hepatitis, drug-induced liver disease, autoimmune liver disease, decompensated liver cirrhosis, liver malignancy, or having had a liver transplantation.
• • 3. Pregnant women and lactating women.